A Subcutaneous Biochip for Remote Monitoring of Human Metabolism: Packaging and Biocompatibility Assessment by Cavallini, Andrea et al.
IEEE SENSORS JOURNAL, VOL. 15, NO. 1, JANUARY 2015 417
A Subcutaneous Biochip for Remote Monitoring
of Human Metabolism: Packaging and
Biocompatibility Assessment
Andrea Cavallini, Tanja Rezzonico Jost, Seyedeh Sara Ghoreishizadeh, Jacopo Olivo, Maaike Op de Beeck,
Benjamin Gorissen, Fabio Grassi, Giovanni De Micheli, Fellow, IEEE, and Sandro Carrara, Senior Member, IEEE
Abstract— This paper represents the extended version of the
conference paper “Developing highly-integrated subcutaneous
biochips for remote monitoring of human metabolism” pre-
sented at the IEEE Sensors Conference 2012, and presents
data on assembly, packaging and short term in vitro and in
vivo biocompatibility evaluation of a fully implantable biosensor
array. The device was realized integrating three building blocks:
1) a multielectrode platform; 2) an inductive coil; and 3) an
integrated circuit. The entire system measures 2.2 mm × 2.2
mm × 15 mm. Corrosion of electronic components and leaking
of potentially hazardous substances in the body is prevented
with a conformal coating of Parylene C, while an outer package
of medical grade silicone was employed to create a soft shell
suitable for implantation. Biocompatibility experiments did not
show in vitro cytotoxicity in the considered period of 7 days,
while comparison between 7 and 30 days in vivo implantations
showed significant reduction of the inflammatory response in
time, suggesting normal host recovery.
Index Terms— Biosensors, implantable biomedical devices,
electronics packaging.
I. INTRODUCTION
CONTINUOUS monitoring of humans is already in themarket for glucose [1] and lactate [2], thanks to the
electrochemical sensing, and prototypes of fully implantable
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Fig. 1. The fully implantable platform. Left: assembly schematics; right,
packaged device.
glucose sensors have been validated up to 8 month in mice [3]
and up to one year in pigs [4]. The next step will be the
extension of this technology to other relevant metabolites
such as, glutamate [5], ATP [6] and drugs [7], [8]. An open
challenge is the integration of all these metabolites in a
subcutaneous biosensor array capable to provide minimally
invasive human telemetry. Such system must satisfy several
requirements: sensitivity, as the operative concentration of
the biosensor must correspond to the therapeutic range of
the target compound in the body; specificity, as the sensors
must be able to operate in complex solutions like plasma or
interstitial fluid without detecting any interferant; autonomy,
as the device must be capable to perform automatically the
measurements without the need of external input and without
being subjected to power shortages; biostability, as the device
should remain functional after the insertion; biocompatibility,
because the implant must be well tolerated by the host and
cause a limited foreign body reaction;
In this paper we present a prototype of a fully implantable
device based on three building blocks: a passive chip hosting
5 independent biosensor electrodes, a temperature and a pH
sensor; an inductive coil for the remote powering of the
sensor towards an external wearable device, and an integrated
circuit performing the electrochemical measurements (fig. 1).
Such device represents a novelty compared to the existing
implantable sensors, measuring a single compound, battery
powered, and bearing a hard packaging. The device sensitivity
can be promoted by nanostructuring the electrode surface with
carbon nanotubes (CNT). Although the in-vivo application
of CNT is controversial in healthcare applications due to
discordant results about their safety [9], the addition of CNT
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proved to be essential to detect physiological concentrations of
analytes in human plasma, as demonstrated by our previous
works [7], [8]. Furthermore, various measures are taken to
prevent CNT release from the implant. The presence of
multiple sensors is a strategy to achieve specificity in electro-
chemical drug detection with P450 biosensors: cytochromes
p450 have a broad substrate range and atypical kinetics.
Drugs are detected by cyclic voltammetry, and recognized
by their specific electrochemical signature, a characteristic
potential shift of the p450 reduction peak [10]. The presence
of different biosensors specific for the same target, combined
with a temperature sensor and a pH sensor, enables the correct
interpretation of the electrochemical signature of the analytes
[11], [12]. A battery-less system for the remote powering of
the device [13], and an integrated circuit capable of generating
on-board voltage ramps [14], ensure the device autonomy;
finally, to promote biostability and biocompatibility, we added
a double protection for electrodes and electronic components:
enzymes and CNTs were entrapped in a chitosan (CHT) matrix
and then sealed behind a porous polycarbonate membrane.
Chitosan is a natural polysaccharide with unique biologi-
cal properties including non-toxicity, physiological inertness,
affinity to proteins, hemostatic fungistatic and antitumoral
properties, which already found employ in biosensors [15],
while polycarbonate membranes are commonly employed as
microdialysis filters in commercial biosensors [1]. Corrosion
of electronic components and leaking of potentially hazardous
substances in the body was prevented by a conformal coating
of Parylene C, an inert and biocompatible polymer with wide-
spread industrial use as diffusion barrier. An outer package of
medical grade silicone was then employed to create a soft shell
suitable for implantation. The present work, which represent
an extension of the conference paper “Developing highly-
integrated subcutaneous biochips for remote monitoring of
human metabolism” [16], presented at the conference IEEE
Sensors 2012, focus on the packaging and the short-term
biocompatibility evaluation of our implantable device. The
efficacy of the parylene C barrier, as well as the toxicity of
carbon nanotubes, have been assessed with a 7-day in-vitro
cytotoxicity elution test conform to the ISO-10993-1 standard.
The integrity of the CHT/CNT matrix and the efficacy of
the polycarbonate membrane in preventing CNT leaking were
tested by exposing the materials to solutions of different nature
and pH at 37 °C for one week. The final packaged device
was then implanted in mice for 7 and 30 days to evaluate the
inflammatory response.
II. SYSTEM AND BUILDING BLOCKS DESIGN
A. Passive Chip
Choice of materials and design was done considering
biocompatibility and simplicity of fabrication as of primary
importance. Silicon wafers with 500nm of native oxide were
chosen as substrate. Chip metallization was realized by evap-
oration of 10nm of Ti, followed by 100nm of Pt. Metal
passivation was made via atomic layer deposition of 20nm
of Al2 O3. Passivation openings were made by dry etching
with Argon Ion Milling. Only two masks resulted necessary
Fig. 2. Photographs of the passive chip. Working electrodes were realized in
different geometries: as arrays of 10 and 40 μm and as a single electrode of
500 μm (left); center whole platform right, temperature and pH sensors, pads
for IC integration and schematics of the electrochemical cell. image from [20].
for the whole microfabrication. As substrate, silicon has been
chosen over glass for its better thermal conductibility, in order
to improve the dissipation of heat generated by the integrated
circuit. Pt metallization was chosen for three main reasons:
1) biocompatibility and resistance to corrosion, 2) pseudo-
reference electrode behavior, 3) employment in the fabrication
of resistive thermal devices with a linear range suitable to
measure physiological temperatures [17]. Al2 O3 is a biocom-
patible material already used in biomedical coatings [18].
Atomic layer deposition was chosen among other techniques
for its capability to generate thin, uniform and pinhole free
passivations [19]. Figure 2 shows photographs of the passive
chip: the platform measures 2.2 × 15mm, and host five
independent platinum working electrodes (WE) with common
reference (RE) and counter (CE) electrodes; a pH sensor
based on an anodic iridium oxide film; a resistive platinum
thermal device (Pt RTD) as temperature sensor, and pads for
the wire bonding of the integrated circuit. The inclusion of
common reference and counter electrode allowed simplifying
the interconnections with the sensing circuitry, optimizing at
the same time the available space. The working electrodes
can be individually functionalized with high precision towards
a single-step electrodeposition of a solution containing CHT
0.7% w/v; MWCNT 1% and the enzyme at an appropriate
working concentration (i.e. 15 mg/ml). The polarization of an
electrode at +1.5 mV for at least 300” creates a localized
region of high pH that can exceed chitosans solubility limit,
allowing CHT polymerization and the entrapment of any other
compound present in the original solution with high spatial
selectivity, while variations in the electrodeposition time allow
to control the amount of material deposited. Characterization
of the electrodes, biosensors, electrodepositon, pH and tem-
perature sensors is extensively reported in [20].
B. Measurement Circuit
In order to integrate sensors and electronics into a single
device, the front-end electronics for the realization of the two
mostly used detection techniques, Chronoamperometry (CA)
and Cyclic Voltammetry (CV), must be carefully designed.
At present, there is little literature concerning the integration
of the waveform generator to the implantable biochip which
is essential for a fully-integrated CV measurement [21], [22],
and most of the designed electronics for the biosensors use an
external generator. Li et al. described a ramp generator circuit
CAVALLINI et al.: SUBCUTANEOUS BIOCHIP FOR REMOTE MONITORING OF HUMAN METABOLISM 419
Fig. 3. Proposed architecture for the frontend electronics.
that can be integrated in a biosensor array [23]; however the
system presented has limited versatility, since all the electrodes
in the array are subjected to the same potential. In our work
the CE and RE are shared while each WE is designed to
host different biosensors requiring different potentials, or even
different methods to be activated. For this reason, a specific
voltage, either fixed or varied in time, must be applied to each
WE to enable the sensing of the various compounds. Fig. 3
shows the architecture of the proposed frontend electronics,
which consists of three main parts: 1) a ramp generator circuit,
2) a potentiostat, and 3) a current readout circuit. The ramp
generator produces a very-low slope and a low-frequency ramp
voltage, and is capable to generate a triangular waveform with
a slope adjustable from less than 10 mV/sec to more than
100 mV/sec with a rail-to-rail swing. The steps are 3.3mV
and the size of the circuit is 0.122mm2 [24]. The circuit is
based on the Direct Digital Synthesis method (DDS), which
includes a numerically controlled oscillator and a Digital-to-
Analog Converter (DAC). The oscillator produces a quantized
version of the desired waveform, whose period is controlled by
the digital word contained in the Frequency-Control-Register
(FCR). The resulting waveform is then converted to analog by
the DAC [24].
The circuit has been implemented in 0.18μm technology.
Simulations are done using the electrical equivalent model of
the biosensor from [25]. Simulation results show the readout
circuit senses currents in the range of +/− 5μA with an
equivalent input referred current noise of 3nA rms. Highly
controllable low triangular waveform is also achieved. Further
simulation and measurement results on the measurement cir-
cuit are reported in [14], [24], and [26]. The maximum power
consumption of the measurement circuit is 530μW, a value
suitable for the remote powering of our device.
C. Receiving Coil
Remote powering through inductive link is one of the most
promising approaches to supply power to implantable devices,
and the miniaturization of power-efficient inductors, is still an
open topic. To this end, we propose an implantable coil based
on the multi-layer approach. Such strategy, already exploited
in integrated circuits [27], [28], it is not yet commonly used
on printed circuit boards (PCB). In a multi-layer coil, a spiral
inductor is replicated on the two layers of different PCBs.
The boards are then stacked, and the inductors are electrically
connected as shown in fig. 1. Our coil was obtained by using
a 12-layers, 21-turns inductor of 30 mm with a thickness
of 816.4μm. Due to the higher number of turns, our coil
has an improved coupling with the external receiver when
compared to a single-layer coil of equivalent surface [29].
The system also performs bidirectional data communication
without any implanted RF transmitter: downlink communi-
cation is obtained via Amplitude Shift Keying (ASK), while
uplink communication exploits a backscattering technique.
In backscattering, the internal load is modulated according
to the outgoing bit-stream; this change is detected by the
external part as a variation of the current flowing on the
external inductor. A high efficiency class-E power amplifier
was utilized to drive the external inductor. Powered by two
thin lithium-ion polymer batteries, the system can transfer
up to 15mW over a distance of 6mm in air. The maximum
link efficiency measured was 13%. Furthermore, the system
can transfer up to 1.17mW when a 17mm beef sirloin is
placed between the inductors, which is enough power for the
measurement circuit.
III. BIOCOMPATIBILITY ASSESSMENT -
MATERIALS AND METHODS
A. Matrix Corrosion Test
CHT/CNT dispersion was prepared according to [6]. Drops
of 10μl were cast onto a 12 well plate and dried under laminar
flow. Half of the samples were protected with a polycarbonate
membrane (Cyclopore track etched membrane, cut off 100nm,
Whatman) and sealed with fast curing medical grade silicone
(Med2-4220, Nusil). All samples were covered with 1ml
solutions of milliQ water, PBS 1× pH4, or Mouse Embryonic
Fibroblasts (MEF) growth media, and put in a cell incubator
at 37 °C (5% C O2) for 7 days. The 8th day the solutions were
removed and the samples rinsed twice with DI water before
being dried in air under laminar flow. The CHT/CNT matrix
integrity and the dispersion of CNT aggregates on the well
plate surface were then inspected with an optical microscope.
B. In-Vitro Cytotoxicity Test
Preparation of Contaminated Medium: The growth medium
was obtained adding to a Dulbecco Modified Eagle Medium,
Fetal Calf Serum (10% v/v); L-glutamine 200 mM (1% v/v);
Glutamax (2% v/v); non-essential aminoacids (1% v/v), Peni-
cillin/Streptavidin (1% v/v). All the reagents were purchased
from Gibco. Test materials were placed in cell culture dishes,
sterilized with ethanol 70% and dried under laminar flow.
MEF medium was added according to the ratio 1ml/6cm2
of material. The samples were put in a cell incubator at
37 °C, 5% C O2 for 7 days. A negative control of fresh,
uncontaminated MEF medium was also included to account
for the aging of nutrients in solution. The contaminated
medium and the control were then collected, stored at 4 °C
and used within 3 days. Cell culture: Mouse Embryonic
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Fibroblasts (MEF) were extracted, seeded in 12-well plates
at the concentration of 1.2 × 104 cells/ml and grown for
3 days. The 3t h day, the growth medium was collected and
replaced with the contaminated terrain and the control. Cells
were grown for 4 additional days before being inspected for
viability and toxicity. Assessment of Viability: The specimens
were rejected when the viability of healthy control cells
resulted less than 75% [30]. Control wells were incubated 30
with 1μg/ml of DAPI and PI fluorescent dyes (Invitrogen)
to highlight respectively total cell nuclei and dead cells. For
each well, three DAPI and PI counts in different spots were
performed. Cell viability was then calculated according to the
equation
viabili ty = viable cells
total cells
100% (1)
where viable cells is the total number of DAPI counts minus
PI counts and total cells is total number of DAPI counts.
Toxicity Evaluation: Cells were incubated 30 with 1 μg/ml
of Calcein AM (Invitrogen). The fluorescence in each sample
was immediately measured with a commercial scanner (Tecan
infinite M1000, excitation λ485nm, emission 525nm). The
total fluorescence count for each well was obtained averaging
225 readings evenly distributed in a 15 × 15 round shape
along the well area. Since Calcein AM stains only living cells,
cytotoxicity was evaluated comparing the fluorescence inten-
sity of the contaminated samples with the control. According
to the United States Pharmacopeia (USP) standards, intensity
decrease of more than 20% from the control was considered
cytotoxic. Additionally, cells were inspected for morphologic
abnormalities by fluorescence microscopy. Samples presenting
a majority of abnormal cells with respect to the control were
considered cytotoxic.
C. Assembly and Packaging
Loctite 3211 USP class VI biocompatible glue was pur-
chased from Loctite. Adhesion promoter Silane A174 was
obtained from Merck and applied to the samples according
to the procedure described in [31]; Parylene C was bought
from Speciality Coating Systems and deposited by chemical
vapor deposition using a Comelec C-30-S Parylene Deposition
System. The plexiglass mold for the final silicone encapsula-
tion was realized by micromachining. Biocompatible medical-
grade silicone (Med-6033) was bought from Nusil.
D. In-Vivo Biocompatibility
Microchips were cleaned and disinfected with Gigasept
instru AF (Schuelke), placed in cell culture dishes, sterilized
with ethanol 70% and dried under laminar flow. An Air Pouch
(AP) was created by subcutaneous injection of sterile air in the
back of male C57BL/6 mice at day 1 (5mL) and day 3 (3mL);
this procedure creates a cavity of 1.5cm diameter and 0.5cm
height. At day 6, mice were anesthetized with isoflurane 4%,
shaved and locally sterilized with Betadine Solution; the sterile
microchips were implanted and the cavity sutured with Vicryl
6.0 (Provet AG). As a control of local inflammation, bacterial
lipopolysaccharide (LPS) (50g/mouse) (LabForce AG) was
Fig. 4. Corrosion test of the CHT/CNT matrix. Black spots represent chunks
of CHT/CNT attached to the surface. A, B evaluation of CHT/CNT leaking
from a polycarbonate membrane.
injected daily into the cavity for 4 days or 2 weeks for short
term and long term biocompatibility, respectively. As negative
control air pouches were generated in the absence of any
surgical procedure. After 7 or 30 days, the microchips were
removed. The cavity was rinsed with 0.5mL of PBS (Gibco)
and the liquid collected and centrifuged at 7000rpm for 10’
at 4 °C. We then determined the concentration of ATP in
the supernatant with ATP detection kit (ATP Determination
Kit, Invitrogen). For polymorphonuclear neutrophils detec-
tion, the pellet was resuspended in 0.2mL RPMI 10% fetal
bovine serum (FBS) (Gibco) and analyzed at flow cytometer
(FACS Canto, Becton Dickinson) with antibodies specific for
CD11b and Gr1, respectively labeled with allophycocyanin
(APC) and fluorescein isothiocyanate (FITC) (both from
BioLegend).
IV. BIOCOMPATIBILITY ASSESSMENT - RESULTS
AND DISCUSSION
A. Matrix Corrosion Test
To assess if the CHT/CNT matrix represent a good strat-
egy for enzyme immobilization in implantable sensors, we
tested its resistance to corrosion in different solutions: PBS
1× pH4, distilled (DI) water, and MEF medium after 7 days of
incubation at 37 °C (5% CO2) (fig. 4). Data shows at acidic pH
CHT/CNT aggregates are spread on the well surface and tend
to accumulate at the well edge. The extent of matrix corrosion
is due to the different solutions pH: chitosan has a pKa
of ∼= 6.5. When the solution pH is lower than chitosan pKa ,
the amino-groups of chitosan are protonated and the compound
becomes water soluble. Differences in corrosion between water
and MEF medium are attributed to the buffer properties of
the latter: cell substrates are optimized to maintain a phys-
iological pH during the incubation. In a second experiment
we evaluated if the presence of a polycarbonate membrane
is sufficient to prevent significant CNT leaking in the body.
After 7 days of incubation in PBS 1× pH4, the matrix drop
is still evident, but a darker area in its proximity denotes the
presence of severe corrosion fig. 4 (A). Optical microscope
images of the silicone seal edge fig. 4 (B) clearly show that
CNTs and chitosan in solution are able to leak from the
membrane.
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Fig. 5. Evaluation of materials cytotoxicity by calcein staining - average
fluorescence values. Error bars, standard deviation (1σ ).
B. In-Vitro Citotoxicity Test
The building blocks of the implantable sensor are partially
made from non-biocompatible or potentially toxic materials.
For example, the receiving coil presents a copper metalliza-
tion, notably cytotoxic [32], while materials of the integrated
circuit and of the auxiliary electric components, realized by
external companies, are not totally disclosed, and have to be
considered as potentially harmful. A conformal coating of
3μm parylene C was employed to prevent both corrosion of
the electrical parts and toxic metals leaking in the surrounding
tissue. Parylene efficacy was evaluated by elution tests using
the copper receiving coil as test substrate. When immersed
in a fluid, the copper contained in the coil diffuses in the
solution, producing severe cytotoxicity even at very small
concentrations. Cytotoxicity was assessed with elution tests
according to the ISO 10993-1 guidelines. Each experiment was
conducted in triplicate and included a positive control to assure
reproducibility and reliability of results. Fig. 5A presents the
average fluorescence of Calcein-AM stained cells. After 4 days
of incubation with the contaminated medium, cells grown in
presence of the terrain eluted with the unprotected coil yielded
severe cytoxicity, as demonstrated by very low fluorescence;
On the other hand, the parylene C coating proved effective
in preventing severe cytotoxicity, as the fluorescence intensity
resulted the 88% of the intensity of the control (cells grown
in uncontaminated medium). It is worth mentioning that while
variations up to 20% from the control are not considered
cytotoxic by the USP guidelines, such variability could be
unacceptable in long term implants [30]. The protection of the
parylene C coating can be enhanced improving its substrate
adhesion and its thickness. Accelerated elution tests performed
on our silicon electrodes (3 days at 70 °C in PBS 1× pH7.4),
showed that coatings of 3μm on surfaces not treated with
adhesion promoter, tend to form bubbles and eventually detach
from the surface (fig. 7). In a second experiment we evaluated
the cytotoxicity of the CHT/CNT matrix (fig. 6B). After 7 days
of elution and four days of incubation with healthy cells,
no significant differences with the control cells have been
observed, proving that in the considered period the CNT
leaking is not cytotoxic. A possible explanation is that CNT
toxicity depends on many factors like length, functionalization
or aggregation [9], [33]. Also, the tight wrapping of chitosan
to the nanotubes, which is also responsible for their dispersion
in aqueous solutions [34], might shield the nanoparticle and
its reactive groups, reducing the inherent toxicity and pre-
venting their aggregation. The lack of short-term cytotoxicity
of chitosan/CNT nanocomposites is a very promising result
towards the employment of this nanomaterial in biomedical
Fig. 6. Morphology of MEF grown in different contaminated media.
A) control, B) protected coil, C) CHT/CNT matrix, and D) unprotected coil.
Fig. 7. Accelerated elution test of the sensor platform covered by 3μm of
parylene C. Optical microscope images. A) Before the test; B) ater 1 week
at 37 °C in MEF medium; and C) after 3 additional days at 70 °C in MEF
medium.
applications; however, it is important to say that the application
of carbon nanotubes in implantable devices relies strongly
on their long-term safety: at best of our knowledge, up to
date there are no exhaustive studies concerning the long-
term effects of functionalized CNT in living organisms or the
impact of these substances on the environment. As additional
cytotoxicity control we performed a morphological analysis of
the cells exposed to the elution fluids. Fig. 6 shows that cells
from the protected coil (B) and from the CHT/CNT matrix
(C) are similar in shape and distribution to the control (A).
No living cells were found on the sample with fluid eluted
from the unprotected coil (D, bright field image). The giant
cells shown in the pictures are due to the initial cell density,
which after 7 days resulted too low to give a confluent cover-
age and the typical tight and elongated shape of fibroblasts.
C. Assembly and Packaging
The sensor building blocks were glued together using a
USP class VI biocompatible glue. Component interconnection
was realized with Al wire bonding and protected with glob
top. To further improve parylene C adhesion and moisture
penetration, the assembled platform was treated with silane
A-174 and coated with 16μm of parylene C. The outer
silicon shell was realized by placing the implant into a
plexiglass mold and injecting biocompatible medical-grade
silicone. To increase the host comfort, the outer shell was
made 1mm thick and with rounded corners. In a design
variant, two wingsof 3 × 3mm placed along the main body
have been included to prevent the sensor to capsize after
implantation, since misalignment between the receving coil
and the external wearable device can compromise the remote
powering of the sensor array. 0.1μl of CHT/CNT suspension
was then manually drop cast on the electrodes and dried in air.
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Fig. 8. In-vivo biocompatibility results after 7 and 30 days. Top: neutrophils
infiltration in the implant cavity (%); bottom, ATP concentration. Error bars,
standard deviation (1σ ).
A polycarbonate membrane was placed above the electrodes
and sealed to the external shell using fast curing medical grade
silicone. Without considering the external wings, the packaged
device measures 20 × 4.2 × 3mm. The final device is shown
in fig. 1.
D. In-Vivo Biocompatibility
Potential sources of inflammation in implantable devices,
can be attributed to the implant materials, shape and dimen-
sions [35]. In order to investigate which elements are critical
in eliciting an inflammatory response, we fabricated devices
of different nature and shape to subcutaneously implant in
mice. To account for inter-individual variability, each model
was tested in eight different animals. Half of the mice carried
the implant for 7 days, the other half for 30 days. At the
end of the period, the implant site was washed with PBS,
and levels of ATP and neutrophils in the elution liquid were
compared to follow the local inflammatory response. While
ATP release is a consequence of cellular necrosis and it is
therefore a measure of the local cell damage, neutrophils
are recruited to the inflammation site by chemical signaling.
Variations in neutrophil percentage at the implant site are
therefore informative of the status of tissue inflammation [36].
Fig. 8 presents neutrophils and ATP variation in the liquid
collected from the implant site after 7 and 30 days. Sensors
packaged with a soft shell with or without external wings (W),
were compared with dummy package replicas entirely made
in biocompatible silicone. Bacterial lipopolysaccharide (LPS)
was administered to a separate group of mice in order to induce
an inflammatory response not caused by an artificial implant
(positive control), while mice with air pouch only served as
negative control.
After 7 days, we measured high levels of ATP and neu-
trophils, but both values substantially decreased after 30 days
in a way proportional to the insert complexity (presence of
wings and/or sensors), suggesting that the organism became
tolerant to the implants. Data from neutrophils suggests that
the insert complexity (presence of wings and/or sensors)
tends to increase the short-term and long-term inflammatory
response. Considering average values, after 30 days, residual
neutrophils in mice treated with winged inserts were 2-3 folds
higher than their counterparts, while the presence of the sensor
platform induced slightly higher inflammatory responses. ATP
measurements in mice bearing the implant were affected by
large statistical variability. A possible explanation is that upon
removal we found that several implants were displaced from
their original location. This may have led to internal tissue
damage due to mechanical friction, and therefore insurgence
of cellular damage and ATP release in some individuals [37].
Unfortunately, this large variation in the ATP measurements
makes difficult to establish a clear relationship between
implant complexity and extent of local cell death.
Values from LPS injection further suggest how after 30 days
the host seems to accept the insert. Although LPS-induced
ATP and neutrophils were detected in lower amounts compared
to the values obtained from implants, ATP concentration in
animals treated with LPS almost doubled after 30 days. The
pyrogenic effect of LPS is also evident with respect to the neu-
trophils infiltration: in one month, LPS-treated mice presented
the highest percentage of neutrophils and the slightest time-
dependent reduction among the animals considered. From the
neutrophils measurements it appears that the package shape
has a role in determining the inflammatory response, as the
presence of wings tends to increase the immune reaction.
Although the introduction of stitching wings may be necessary
to hold the insert in place and correctly aligned with the
external powering coil, their presence can exert an uncom-
fortable localized pressure on some parts of the tissue, and
angles where tissue stress might promote localized immune
responses [38]. The presence of the electronic platform further
increased the inflammation response. However, it is important
to say that more than strong conclusions, these are trends
suggested by the average values obtained. In-vivo experiments
tend to have large variability, and due to the reduced number of
animals used, the overlap of error bars indicates that results are
not statistically different. A larger number of experiments, or
different investigation techniques are advised for a more pre-
cise evaluation of the in-vivo biocompatibility. The removal of
copper components from the sensor electronics, together with
thicker parylene coatings may further reduce the inflammation
caused by the biosensor platform. The reduction of implant
dimensions may also help increasing the host tolerance. In this
respect, the bulkiest component of our platformis the inductive
coil, which with a thickness of 2mm, contributes to almost 4/5
of the total platform volume. Our group is currently developing
a single layer coil on silicon, which will reduce the platform
thickness to 11.5mm.
V. CONCLUSION
This paper represent the extended version of the work
descrived in reference [16], and presents a novel, highly
integrated system for human metabolism telemetry, focusing
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on its packaging and biocompatibility. The system is made of
three parts: a passive chip hosting 5 independent biosensors,
a pH sensor and a temperature sensor; a CMOS integrated
circuit capable to perform the required electrochemical mea-
surements, and a multi-layer antenna for the remote powering
of the device and the transmission of the sensing data. The
electrodes of the passive chip can be functionalized with
proper bio and nanostructures with high spatial precision
towards electrodeposition of a solution of chitosan, carbon
nanotubes and enzymes [16]. The CMOS IC showed good
performance in simulations and measurements [24], [26], [39],
while the receiving antenna resulted capable to collect enough
energy to support the work of the IC [16]. The assembled
system was packaged with an inner barrier of parylene C,
an outer shell of biocompatible silicone and a polycarbonate
membrane to protect the sensor area. The biocompatibility of
the device was then tested in-vitro and in-vivo.
In-vitro experiments on primary fibroblasts proved that
coatings of 3M of parylene C are effective in preventing
copper leaking and cytoxicity for at least seven days; similar
test on a chitosan/MWCNT matrix showed that release of
chitosan/MWCNT complexes in the growth terrain are not
cytotoxic in the short term. This last result is in agreement
with recent studies demonstrating that the employ of short,
functionalized CNT immobilized in a nanocomposite may be
implemented with a certain degree of safety. Although, in
last analysis, the fate of nanotubes in implantable devices is
still largely dependent by studies concerning their long-term
toxicity. In-vivo tests of the packaged sensor array demon-
strated that the foreign body reaction significantly decreased
after 30 days, suggesting normal recovery of the host. Package
shape is suspected to have a role in inducing the inflamma-
tory response, suggesting that future implants must possess
smoother and simpler geometries.
Taken all together, these results demonstrate the feasibil-
ity of the entire system. Future works will be directed in
assessing the performance of the fully implantable system
in autonomous measurements in-vitro of different metabolites
and in promoting the long-term biocompatibility and biosta-
bility of the device.
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